Sanofi, Regeneron prevail against Amgen at EPO
30-10-2020
Amgen prevails against Sanofi and Regeneron
26-02-2019
Federal Circuit vacates Amgen injunction in Sanofi suit
06-10-2017
Mari / iStockphoto.com
Sanofi and Regeneron have secured a stay of an injunction that would have blocked the companies from selling their cholesterol-lowering drug Praluent (alirocumab) injection.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Federal Circuit, Praluent, injunction, patent, Amgen, Sanofi, Regeneron
